Dario A. Paggiarino - 25 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
25 Jan 2024
Net transactions value
-$7,191
Form type
4
Filing time
29 Jan 2024, 17:51:57 UTC
Previous filing
25 Jan 2024
Next filing
30 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $3,939 +300 +0.82% $13.13 36,805 25 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $3,870 +300 +0.82% $12.90 37,105 25 Jan 2024 Direct
transaction EYPT Common Stock Sale $7,500 -300 -0.81% $25.00 36,805 25 Jan 2024 Direct
transaction EYPT Common Stock Sale $7,500 -300 -0.82% $25.00 36,505 25 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -300 -0.58% $0.000000 51,304 25 Jan 2024 Common Stock 300 $13.13 Direct F1
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -300 -1.8% $0.000000 16,635 25 Jan 2024 Common Stock 300 $12.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
F2 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020